Estrogen-receptor negative breast cancer

This study tests different hormone therapies in men with breast cancer before they have surgery. The goal is to see which treatment works best to shrink the tumor. About 60 men with hormone receptor-positive breast cancer will take part.

This study tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy in about 500 people with advanced triple-negative or ER-low breast cancer who cannot receive immunotherapy. The drug is designed to target and kill cancer cells while sparing hea…

This phase 2 trial is testing whether the investigational drug datopotamab deruxtecan (Dato-DXd) can safely and effectively treat HER2-negative breast cancer that has spread to the brain. The study enrolls adults with metastatic breast cancer who have brain metastases that are ei…

This phase 2 study is testing a drug called sacituzumab govitecan, alone or with pembrolizumab, given before surgery to people with localized triple-negative breast cancer. The goal is to see if these drugs can eliminate all cancer cells in the breast and lymph nodes before surge…

This study is for people with certain types of breast cancer (HER2-positive or triple-negative) who have a complete response to initial drug therapy. It tests whether they can safely skip surgery and only receive radiation, or skip radiation if surgery shows no cancer left. For a…

This study tests whether a 10-week stress reduction program is doable and helpful for people with triple negative breast cancer. The program includes relaxation, coping skills, and social support, and also addresses basic needs like utilities or transportation. Researchers will m…

This study is for people with metastatic breast cancer, including estrogen receptor-positive and triple-negative types. It uses biomarkers from tumors and blood to guide treatment choices, comparing how long the cancer stays controlled on the new therapy versus the previous one. …